Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness—a protocol for a randomised controlled trial (ASTUTE trial)

Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness—a protocol for a randomised controlled trial (ASTUTE trial)

Introduction Adalimumab is an effective treatment for autoimmune non-infectious uveitis (ANIU), but it is currently only funded for a minority of patients with ANIU in the UK as it is restricted by the National Institute for Health and Care Excellence guidance. Ophthalmologists believe that adalimum...

Full description

Saved in:
Bibliographic Details
Main Authors: Chris A Rogers, Andrew Dick, Tunde Peto, Robert Wilson, Pearse A Keane, Alastair K Denniston, Srilakshmi M Sharma, Lucy Culliford, Katie Pike, Sarah Baos, Carlos Pavesio, Sarah Wordsworth, Barnaby Reeves, Annie Folkard, Mae Hazell, Mandy P Y Lui, Nicholas A V Beare
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/1/e082246.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/1/e082246.full

Similar Items